Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

NCT00669903 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
100
Enrollment
INDUSTRY
Sponsor class

Stopped Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to stop further development of AZD0328

Conditions

Interventions

Sponsor

AstraZeneca